Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adenomatous Polyposis Coli Clear all
Completed Phase 2 Interventional Results available

Curcumin in Treating Patients With Familial Adenomatous Polyposis

NCT00641147
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Curcumin, Laboratory Biomarker Analysis, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Jul 21, 2026, 7:27 PM EDT
Terminated No phase listed Observational Results available

Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients

NCT00151476
View directory record Official record
Conditions
Familial Adenomatous Polyposis (FAP)
Interventions
Celecoxib, Routine Medical Care
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Jul 21, 2026, 7:27 PM EDT
Completed Phase 2 Interventional Results available

Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers

NCT00503035
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Celecoxib, Colonoscopy Biopsy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Jul 21, 2026, 7:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Surveillance Program

NCT02747862
View directory record Official record
Conditions
Attenuated Familial Adenomatous Polyposis, Deleterious Familial Adenomatous Polyposis
Interventions
Chart Review
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Jul 21, 2026, 7:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

NCT05552755
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
REC-4881, Placebo
Drug
Lead sponsor
Recursion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Scottsdale, Arizona • Tucson, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Active, not recruiting Phase 2 Interventional

Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

NCT04230499
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Encapsulated Rapamycin (eRapa)
Drug
Lead sponsor
Rapamycin Holdings Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Jul 21, 2026, 7:27 PM EDT
Recruiting No phase listed Observational

Familial Investigations of Childhood Cancer Predisposition

NCT03050268
View directory record Official record
Conditions
Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2037
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Completed Phase 1 Interventional

A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis

NCT05014360
View directory record Official record
Conditions
Adenomatous Polyposis Coli
Interventions
JNJ-64251330
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Duarte, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Jul 21, 2026, 7:27 PM EDT
Terminated Not applicable Interventional Results available

An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal Surgery

NCT01002287
View directory record Official record
Conditions
Ulcerative Colitis, Familial Polyposis
Interventions
SprayShield Adhesion Barrier System, Good Surgical Technique Alone
Device · Procedure
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Jul 21, 2026, 7:27 PM EDT
Terminated Phase 2 Interventional

Testing Obeticholic Acid for Familial Adenomatous Polyposis

NCT05223036
View directory record Official record
Conditions
Attenuated Familial Adenomatous Polyposis, Colorectal Carcinoma, Duodenal Carcinoma, Familial Adenomatous Polyposis
Interventions
Biopsy Procedure, Biospecimen Collection, Gastrointestinal Endoscopy, Obeticholic Acid, Placebo Administration, Questionnaire Administration
Procedure · Biological · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Scottsdale, Arizona • Kansas City, Kansas • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Terminated Phase 3 Interventional Results available

Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)

NCT00585312
View directory record Official record
Conditions
Adenomatous Polyposis Coli
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
23
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Omaha, Nebraska + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Jul 21, 2026, 7:27 PM EDT
Recruiting Not applicable Interventional

Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)

NCT06641310
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Exercise Therapy
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Completed Phase 1 Interventional Results available

Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)

NCT00770991
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Black raspberry (BRB) Slurry, Black Raspberry (BRB) Suppositories, Black Raspberry (BRB) Placebo Slurry
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Jul 21, 2026, 7:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT05919264
View directory record Official record
Conditions
Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, FAP, Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, Adamantinomatous Craniopharyngioma
Interventions
FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab
Drug
Lead sponsor
Parabilis Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Completed No phase listed Observational

Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer

NCT00675636
View directory record Official record
Conditions
Colorectal Cancer, Hereditary Non-polyposis Colon Cancer, Precancerous Condition
Interventions
study of socioeconomic and demographic variables, evaluation of cancer risk factors, study of high risk factors
Other · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 100 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Jul 21, 2026, 7:27 PM EDT
Terminated No phase listed Observational

Ileal Pouch-Anal Anastomosis Registry

NCT01026480
View directory record Official record
Conditions
Ileal Pouch-Anal Anastomosis
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
Not listed
Enrollment
936 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Jul 21, 2026, 7:27 PM EDT
Completed Phase 1 Interventional

A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

NCT03649971
View directory record Official record
Conditions
Adenomatous Polyposis Coli
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
18
States / cities
Phoenix, Arizona • Duarte, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 21, 2026, 7:27 PM EDT
Completed Phase 3 Interventional Results available

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

NCT01483144
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Eflornithine, Eflornithine Placebo, Sulindac 150 MG, Sulindac placebo
Drug
Lead sponsor
Cancer Prevention Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
10
States / cities
La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Jul 21, 2026, 7:27 PM EDT
Terminated No phase listed Observational

Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01

NCT04674228
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Electronic Health Record Review
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Recruiting Not applicable Interventional

Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis

NCT06578637
View directory record Official record
Conditions
FAP, Familial Adenomatous Polyposis
Interventions
R-1,3-Butanediol (10G-A), R-1,3-Butanediol (20G-A), R-1,3-Butanediol (30G-A), R-1,3-Butanediol (30G-B)
Dietary Supplement
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 21, 2026, 7:27 PM EDT
Completed No phase listed Observational

Visualization of the Papilla Through Use of the NuView Device in Patients With FAP

NCT05657145
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

NCT06950385
View directory record Official record
Conditions
Familial Adenomatous Polyposis (FAP)
Interventions
eRapa (encapsulated rapamycin), Placebo
Drug
Lead sponsor
Rapamycin Holdings Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
18
States / cities
Arcadia, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Integrated Cancer Repository for Cancer Research

NCT02012699
View directory record Official record
Conditions
Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 110 Years
Enrollment
999,999 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
42
States / cities
Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

NCT07463599
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC), Adenomatous Polyposis Coli (APC) Gene Mutation, Catenin Beta-1 (CTNNB1) Gene Mutation
Interventions
Tegavivint
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 21, 2026, 7:27 PM EDT